ASSOCIATION OF HYPERTENSION AND PROTEINURIA WITH OVERALL SURVIVAL IN SOLID-TUMOR PATIENTS TREATED WITH ANTI-VEGF DRUGS IN THE MARS STUDY.
Author(s): Vincent Launay-Vacher, Nicolas Janus, Isabelle Laure Ray-Coquard, Philippe Beuzeboc, Catherine Daniel, Joseph Gligorov, Frédéric Selle, et al
Conference: 2014 ASCO Annual Meeting
Location: Chicago IL Date: May 30-June 02, 2014
Source: J Clin Oncol 32:5s, 2014 (suppl; abstr 2548)

ASSOCIATION BETWEEN INHERITED THROMBOPHILIC ABNORMALITIES AND CENTRAL VENOUS CATHETER THROMBOSIS IN PATIENTS WITH CANCER: RESULTS OF THE CAVECCAS STUDY.
Author(s): Philippe Debourdeau, Marc Espie, Joseph Gligorov, et al
Conference: 2014 ASCO Annual Meeting
Location: Chicago IL Date: May 30-June 02, 2014
Source: J Clin Oncol 32:5s, 2014 (suppl; abstr e20616)

A PHASE II RANDOMIZED OPEN-LABEL STUDY OF MM-121, A FULLY HUMAN MONOCLONAL ANTIBODY TARGETING ERBB3, IN COMBINATION WITH WEEKLY PACLITAXEL VERSUS WEEKLY PACLITAXEL IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCERS.
Author(s): Joyce Liu, Isabelle Laure Ray-Coquard, Frédéric Selle, et al
Conference: 2014 ASCO Annual Meeting
Location: Chicago IL Date: May 30-June 02, 2014
Source: J Clin Oncol 32:5s, 2014 (suppl; abstr 5519)

A RANDOMIZED, OPEN-LABEL, PHASE II STUDY ASSESSING THE EFFICACY AND THE SAFETY OF BEVACIZUMAB IN NEOADJUVANT THERAPY IN PATIENTS WITH FIGO STAGE III/IV OVARIAN, TUBAL, OR PERITONEAL ADENOCARCINOMA, INITIALLY UNRESECTABLE
Author(s): Roman Rouzier, Philippe Morice, Anne Floquet, Frédéric Selle, et al
Conference: 2014 ASCO Annual Meeting
Location: Chicago IL Date: May 30-June 02, 2014
Source: J Clin Oncol 32:5s, 2014 (suppl; abstr TPS5614)

PENELOPE/AGO-OVAR 2.20: A DOUBLE-BLIND PLACEBO (PLA)-CONTROLLED RANDOMIZED PHASE III ENGOT TRIAL EVALUATING CHEMOTHERAPY (CT) WITH OR WITHOUT PERTUZUMAB (P) FOR PLATINUM-RESISTANT OVARIAN CANCER.
Author(s): Christian Kurzeder, Jose Maria Del Campo, Patricia Pautier, Felix Hilpert, Angiolo Gadducci, Petronella Ottevanger, Domenica Lorusso, Ignace Vergote, Isabel Bover, Michel Fabbro, Frederik Marmé, Yolanda Garcia, Frédéric Selle, et al
Conference: 2014 ASCO Annual Meeting
Location: Chicago IL Date: May 30-June 02, 2014
Source: J Clin Oncol 32:5s, 2014 (suppl; abstr TPS5613)

RESULTS OF THE MARS STUDY ON THE MANAGEMENT OF ANTIANGIOGENICS' RENOVASCULAR SAFETY IN LUNG CANCER
Author(s): Goldwasser F ; Janus N ; Morere JF ; Ray-Coquard I ; Spano JP ; Gligorov J ; Rey JB ; Daniel C ; Fabre E ; Launay-Vacher V
Conference: 17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity
Location: Amsterdam, NETHERLANDS Date: SEP 27-OCT 01, 2013
Sponsor(s): ECCO; ESMO; ESTRO
FEASIBILITY AND SAFETY OF FRONT-LINE BEVACIZUMAB (BEV)-CONTAINING THERAPY AFTER NEOADJUVANT (NA) CHEMOTHERAPY (CT) FOR OVARIAN CANCER (OC): THE ROSIA EXPERIENCE.

Author(s): Jacob Korach, Nicoletta Colombo, Irina Davidenko, Cesar Mendiola, Frédéric Selle, ROSiA Investigators

Conference: 2013 ASCO Annual Meeting
Location: Chigaco IL Date: May 30, 2013
Source : J Clin Oncol 31, 2013 (suppl; abstr 5541)

PHASE II TRIAL OF VOLASERTIB (BI 6727) VERSUS CHEMOTHERAPY (CT) IN PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER (OC).

Author(s): Eric Pujade-Lauraine, Beatrice E. Weber, Isabelle Ray-Coquard, Ignace Vergote, Frédéric Selle, Jose Maria Del Campo, Jozef Sufliarisky, Inga Tschöpe, Pilar Garin Chesa, Serge Nazabadioko, Korinna Pilz, Florence Joly

Conference: 2013 ASCO Annual Meeting
Location: Chigaco IL Date: May 30, 2013
Source : J Clin Oncol 31, 2013 (suppl; abstr 5504)

RESULTS OF THE MARS STUDY ON THE MANAGEMENT OF ANTIANGIOGENICS' RENOVASCULAR SAFETY IN OVARIAN CANCER.

Author(s): Vincent Launay-Vacher, Nicolas Janus, Frédéric Selle, Francois Goldwasser, Olivier Mir, Jean-Philippe Spano, Jean Christophe Thery, Philippe Beuzeboc, Jean-Baptiste Rey, Christelle Jouanannad, Jean F. Morere, Stephane Oudard, Joseph Gligorov, Michel Azizi, Richard Dorent, Gilbert Deray, Isabelle Laure Ray-Coquard, Florian Scotte

Conference: 2013 ASCO Annual Meeting
Location: Chigaco IL Date: May 30, 2013
Source : J Clin Oncol 31, 2013 (suppl; abstr 5567)

LMS-02: A PHASE II SINGLE-ARM MULTICENTER STUDY OF DOXORUBICIN IN COMBINATION WITH TRABECTEDIN AS A FIRST-LINE TREATMENT OF ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) AND SOFT TISSUE LMS (ST-LMS): FIRST RESULTS IN PATIENTS WITH U-LMS.

Author(s): Patricia Pautier, Anne Floquet, Didier Cupissol, Benjamin Lacas, Emmanuelle Bompas, Christine Chevreau, Frédéric Selle, Beatrice E. Weber, Cecile Guillemet, Nicolas Penel, Florence Duffaud

Conference: 2013 ASCO Annual Meeting
Location: Chigaco IL Date: May 30, 2013
Source : J Clin Oncol 31, 2013 (suppl; abstr 10505)

RESULTS OF THE MARS STUDY ON THE MANAGEMENT OF ANTIANGIOGENICS' RENOVASCULAR SAFETY IN LUNG CANCER

Author(s): Goldwasser, F ; Janus, N ; Morere, JF ; Ray-Coquard, I ; Spano, JP ; Gligorov J; Rey, JB ; Daniel, C ; Fabre, E ; Launay-Vacher, V

Conference: 17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity
Location: Amsterdam, NETHERLANDS Date: SEP 27-OCT 01, 2013
Sponsor(s): ECCO; ESMO; ESTRO
Source: EUROPEAN JOURNAL OF CANCER Volume: 49 Supplement: 2 Pages: S819-S819 Meeting
Abstract: 3471 Published: SEP 2013

DOES BUFFY COAT PREPARED FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN CANCER PATIENTS HAS PROCOAGULANT PROPERTIES? AN IN VITRO STUDY

Author(s): Sidibe, F ; Vassiliki, G ; Robert, F ; Romain, MP ; Bernaudin, JF ; Lotz JP ; Selle, F ; Larghero, J ; Hatmi, M ; Van Dreden, P ; Gerotziafas, G ; Elalamy, l

Conference: 22nd International Congress on Thrombosis
THE TAXIF II PROTOCOL FINAL RESULTS: A PHASE II TRIAL OF HIGH-DOSE CHEMOTHERAPY SUPPORTED BY HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH DISSEMINATED GERM-CELL TUMORS FAILING CHEMOTHERAPY AND WITH ADVERSE PROGNOSTIC FACTORS
Author(s): Selle, F; Fizazi, K; Biron, P; Gravis-Mescam, G; Bui, B; Bay, J; Flechon, A; Caty, A; Burcoveanu, D; Delva, R; de Revel, T; Miclea, JM; Gaulet, M; Horn, E; Provent, S; Temby, J; Brindel, I; Khalil, J; Gligorov, J; Lotz JP
37th Congress of the European-Society-for-Medical-Oncology (ESMO)
Location: Vienna, AUSTRIA Date: SEP 28-OCT 02, 2012
Sponsor(s): European Soc Med Oncol (ESMO)
Source: JOURNAL OF CLINICAL ONCOLOGY Volume: 30 Issue: 15 Supplement: S
Published: MAY 20 2012

EFFECT OF METASTASIS SURGERY ON OVERALL SURVIVAL IN PATIENTS (PTS) WITH ADVANCED SOFT TISSUE SARCOMA (ASTS): A SUBANALYSIS OF THE PALSAR TRIALS
Author(s): Kotecki, N; Nguyen, BB; Blay, JY; Mathoulin-Pelissier, S; Chevreaux, C; Thariat, J; Cupissol, D; Bay, JO; Coindre, JM; Lotz JP; Jimenez, M; Brouste, V; Guillemet, C; Italiano, A; Penel, N
Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Location: Chicago, IL Date: JUN 01-06, 2012
Sponsor(s): Amer Soc Clin Oncol (ASCO)
Source: JOURNAL OF CLINICAL ONCOLOGY Volume: 30 Issue: 15 Supplement: S
Meeting Abstract: 10035 Published: MAY 20 2012

ROSIA: A SINGLE-ARM STUDY IN MORE THAN 1000 PATIENTS (PTS) RECEIVING FRONT-LINE BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) FOR OVARIAN CANCER (OC)
Author(s): Mendiola, C; Davidenko, I; Colombo, N; Korach, J; Selle F; Gocze, P; Chmielowska, E; Pautier, P; Bollag, D; Oza, AM
Conference: 37th Congress of the European-Society-for-Medical-Oncology (ESMO)
Location: Vienna, AUSTRIA Date: SEP 28-OCT 02, 2012
Sponsor(s): European Soc Med Oncol (ESMO)

FROM A WEBSITE TO A NATIONAL AND REGIONAL REFERENCE CENTRE NETWORK: THE FRENCH EXPERIENCE FOR RARE OVARIAN TUMORS
Author(s): Ray-Coquad, I; Pautier, P; Alexandre, J; Vacher-Lavenu, M; Fabbro, M; Floquet, A; Selle F; Ferron, G; Chiannilkulchai, N; Pujade-Lauraine, E
Conference: 37th Congress of the European-Society-for-Medical-Oncology (ESMO)
Location: Vienna, AUSTRIA Date: SEP 28-OCT 02, 2012
Sponsor(s): European Soc Med Oncol (ESMO)
Source: ANNALS OF ONCOLOGY Volume: 23 Supplement: 9 Pages: 327-327 Published: SEP 2012

SAFETY OF FRONT-LINE BEVACIZUMAB (BEV) COMBINED WITH WEEKLY PACLITAXEL (WPAC) AND Q3W CARBOPLATIN (C) FOR OVARIAN CANCER (OC): RESULTS FROM OCTAVIA.
Author(s): Gonzalez-Martin, A; Gladieff, L; Tholander, B; Stroyakovskyy, D; Gore, ME; Segalla, JGM; Reyners, AKL; Kovalenko, N; Oaknin, A; Selle F; Bollag, DT; Pignata, S
Group Author(s): OCTAVIA Investigators
Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Location: Chicago, IL Date: JUN 01-06, 2012
Sponsor(s): Amer Soc Clin Oncol (ASCO)
MANAGEMENT OF ANTIANGIOGENICS' RENOVASCULAR SAFETY IN OVARIAN CANCER SUBGROUP AND INTERMEDIATE RESULTS OF THE MARS STUDY.

Author(s): Launay-Vacher, V ; Janus, N ; Gligorov, J ; Selle F ; Goldwasser, F ; Mir, O ; Spano, JP ; Thery, JC ; Beuzeboc, P ; Daniel, C ; Rey, JB ; Jouannaud, C ; Morere, JF ; Oudard, S ; Azizi, M ; Deray, G ; Ray-Coquard, I

Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Location: Chicago, IL Date: JUN 01-06, 2012

Source: JOURNAL OF CLINICAL ONCOLOGY Volume: 30 Issue: 15 Supplement: S Meeting

Published: MAY 20 2012

LENALIDOMIDE (REV) IN ASYMPTOMATIC LATE RECURRENT OVARIAN CANCER (ROC) PATIENTS WITH INCREASING CA 125: A GINECO PHASE II TRIAL

Author(s): Selle F ; Ray-Coquard, I ; Sevin, E ; Mari, V ; Berton-Rigaud, D ; Doholou, N ; Fabbro, M ; Floquet, A ; Lesoin, A ; Lortholary, A ; Hardy-Bessard, AC ; Misset, JL ; Mouret-Reynier, MA ; Pujade-Lauraine, E

Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Location: Chicago, IL Date: JUN 01-06, 2012

Source: JOURNAL OF CLINICAL ONCOLOGY Volume: 30 Issue: 15 Supplement: S Meeting

Published: MAY 20 2012

META-ANALYSIS OF PROSPECTIVE EUROPEAN STUDIES ASSESSING THE IMPACT OF USING THE 21-GENE RECURRENCE SCORE ASSAY ON CLINICAL DECISION MAKING IN WOMEN WITH ER-POSITIVE, HER2-NEGATIVE EARLY STAGE BREAST CANCER

Author(s): Albanell, J ; Holt, S ; Gligorov J ; Eiermann, W ; Svedman, C

Conference: 37th Congress of the European-Society-for-Medical-Oncology (ESMO)

Location: Vienna, AUSTRIA Date: SEP 28-OCT 02, 2012


Published: OCT 02, 2012

SAFEHER: A STUDY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB (H-SC) AS ADJUVANT THERAPY IN PATIENTS WITH EARLY HER2-POSITIVE BREAST CANCER (EBC)

Author(s): Gligorov J ; Azim, HA ; Ataseven, B ; Delaurentiis, M ; Jung, KH ; Herbst, F ; Llombart, A ; Manikhas, A ; Osborne, S ; Pivot, X

Conference: 37th Congress of the European-Society-for-Medical-Oncology (ESMO)

Location: Vienna, AUSTRIA Date: SEP 28-OCT 02, 2012


Published: OCT 02, 2012

BEVACIZUMAB-CAPECITABINE (BEV-CAP) AFTER INITIAL 1ST-LINE BEVACIZUMAB-DOCETAXEL (BEV-DOC) IN PATIENTS (PTS) WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC): SAFETY ANALYSIS OF THE IMELDA TRIAL

Author(s): Gligorov J ; Alba-Conejo, E ; Bines, J ; Cortes, PA ; Doval, DC ; Jiang, Z ; Freudensprung, U ; Mustacchi, G

Conference: 37th Congress of the European-Society-for-Medical-Oncology (ESMO)

Location: Vienna, AUSTRIA Date: SEP 28-OCT 02, 2012

Source: European Soc Med Oncol (ESMO)
PROSPECTIVE STUDY OF THE IMPACT OF USING THE 21-GENE RECURRENCE SCORE ASSAY ON CLINICAL DECISION MAKING IN WOMEN WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, EARLY-STAGE BREAST CANCER IN FRANCE.

Author(s): Gligorov J; Pivot, XB; Naman, HL; Jacot, W; Spaeth, D; Misset, JL; Largillier, R; Sautiere, JL; de Roquancourt, A; Pomel, C; Rouanet, P; Rouzier, R; Penault-Llorca, FM

Group Author(s): Francillean Breast Intergrp

Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Location: Chicago, IL Date: JUN 01-06, 2012

Sponsor(s): Amer Soc Clin Oncol (ASCO)

Source: JOURNAL OF CLINICAL ONCOLOGY Volume: 30 Issue: 15 Supplement: S Meeting Abstract: 1051 Published: MAY 20 2012

IMPACT OF BIOMARKERS IN PREDICTIVITY OF THE EFFICACY AND TOXICITY OF A COMBINATION OF PANITUMUMAB PLUS FEC 100 FOLLOWED BY DOCETAXEL IN A PHASE II NEOADJUVANT TRIAL FOR TRIPLE-NEGATIVE BREAST CANCER (TNBC) PATIENTS

Author(s): Nabholtz, Jean-Marc A.; Dauplat, Marie-Melanie; Abrial, Catherine; Gligorov J et al.

Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Location: Chicago, IL Date: JUN 01-06, 2012

Sponsor(s): Amer Soc Clin Oncol (ASCO)


OUTCOME OF HER2-POSITIVE BREAST CANCER PATIENTS FOLLOWING METASTATIC RELAPSE AFTER ADJUVANT TRASTUZUMAB TREATMENT SINCE EMA REGULATORY APPROVAL.

Author(s): Spano, Jean-Philippe; Vignot, Stephane; Ho, Xuan Dung; Gligorov J et al.

Conference: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Location: Chicago, IL Date: JUN 01-06, 2012

Sponsor(s): Amer Soc Clin Oncol (ASCO)


COST-EFFECTIVENESS EVALUATION OF THE 21-GENE BREAST CANCER TEST IN FRANCE

Author(s): Rouzier, R.; Chereau, E.; Laas, E.; Gligorov J et al.

Conference: 4th IMPAKT Breast Cancer Conference

Location: Brussels, BELGIUM Date: MAY 03-05, 2012


PREFHER: A CLINICAL TRIAL TO EVALUATE PATIENT PREFERENCE FOR TRASTUZUMAB ADMINISTERED SUBCUTANEOUSLY OR INTRAVENOUSLY IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER

Author(s): Pivot, X.; Knoop, A.; Curigliano, G.; Gligorov J et al.

Conference: 8th European Breast Cancer Conference (EBCC)

Location: Vienna, AUSTRIA Date: MAR 21-24, 2012

Sponsor(s): European Canc Org (ECCO)

Source: EUROPEAN JOURNAL OF CANCER Volume: 48 Supplement: 1 Pages: S176-S176 Published: MAR 2012

HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL SUPPORT FOR THE HEAVILY PRETREATED PATIENTS WITH GERM CELL TUMOURS: A SERBIAN SINGLE-CENTRE FIRST-EXPERIENCE REPORT

Author(s): Popovic, L; Jovanovic, D; Donat, D; Petrovic, D; Roganovic, T; Lotz JP
EXPERIENCE WITH BEVACIZUMAB IN THE MANAGEMENT OF RELAPSED OVARIAN CANCER - A RETROSPECTIVE OBSERVATIONAL STUDY IN FIVE FRENCH HOSPITALS
Author(s): Dubot, C ; Emile, GA ; Lhomme, C ; Asmane, I ; Pautier, P ; Alexandre, J ; Goldwasser, F ; Lauraine, EP ; Coquard, IR ; Selle F
Conference: European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care
Location: Stockholm, SWEDEN Date: SEP 23-27, 2011
Source: EUROPEAN JOURNAL OF CANCER Volume: 47 Supplement: 1 Pages: S528-S528 Published: SEP 2011

CHEMOTHERAPY AND BEVACIZUMAB COMBINATIONS IN SECOND-LINE OR MORE FOR METASTATIC BREAST CANCER: EFFICACY AND TOXICITY RESULTS
Author(s): Fillette, A ; Guerin, C ; Debrix, I ; Selle, F ; Ontkova, M ; Beerblock, K ; Avenin, D ; Esteso, A ; Lotz JP ; Gligorov, J
Conference: European Breast Cancer Conference
Location: Barcelona, SPAIN Date: MAR 24-24, 2010
Source: EJC SUPPLEMENTS Volume: 8 Issue: 3 Pages: 203-203 DOI: 10.1016/S1359-6349(10)70513-9 Published: MAR 2010

IMPACT OF EPOETIN BETA ON EXECUTIVE FUNCTIONS IN ANAEMIC PATIENTS WITH BREAST CANCER RECEIVING CHEMOTHERAPY: RESULTS OF A PROSPECTIVE COHORT STUDY
Author(s): Pivot, X.; Hugonot-Diener, L.; Coscas, Y.; Gligorov J et al.
Conference: 35th European-Society-for-Medical-Oncology (ESMO)
Congress Location: Milan, ITALY Date: OCT 08-12, 2010
Sponsor(s): European Soc Med Oncol
Source: ANNALS OF ONCOLOGY Volume: 21 Supplement: 8 Pages: 396-396 Published: OCT 2010

PREGNANCY-ASSOCIATED BREAST CANCER IS AS CHEMOSENSITIVE AS CLASSIC BREAST CANCER IN THE NEOADJUVANT SETTING
Author(s): Rouzier, R.; Werkoff, G.; Uzan, C.; Gligorov J et al.
Conference: European Breast Cancer Conference
Location: Barcelona, SPAIN Date: MAR 24-24, 2010
Source: EJC SUPPLEMENTS Volume: 8 Issue: 3 Pages: 64-65 DOI: 10.1016/S1359-6349(10)70054-2 Published: MAR 2010

INDICATIONS OF ADJUVANT CHEMOTHERAPY FOR BREAST CANCER ACCORDING TO LOCAL GUIDELINES, RECURSIVE PARTITION AND ADJUVANTI ONLINE: HOW TO IMPROVE PATIENT MANAGEMENT?
Author(s): Chereau, E.; Coutant, C.; Gligorov J; et al.
Conference: European Breast Cancer Conference
Location: Barcelona, SPAIN Date: MAR 24-24, 2010
Source: EJC SUPPLEMENTS Volume: 8 Issue: 3 Pages: 76-76 DOI: 10.1016/S1359-6349(10)70090-2 Published: MAR 2010
POST-OPERATIVE 5FU-DOCETAXEL AFTER HIGH-DOSE OF PRE-OPERATIVE EPIRUBICIN-CYCLOPHOSPHAMIDE FOR TREATMENT OF INFLAMMATORY BREAST CANCER: RESULTS OF THE FNCLCC-PEGASE 07 TRIAL
Author(s): Viens, P ; Palangie, T ; Ferrero, JM ; Chollet, P ; Bachelot, T ; Delva, R ; Fabbro, M ; Janvier, M ; Lotz JP ; Linassier, C ; Dohollou, N ; Eymard, JC ; Leduc, B ; Geneve, J ; Martin, AL ; Boher, JM ; Roche, H
Conference: 32nd Annual San Antonio Breast Cancer Symposium
Location: San Antonio, TX Date: DEC 09-13, 2009
Source: CANCER RESEARCH Volume: 69 Issue: 24 Supplement: 3 Pages: 618S-619S Published: DEC 15 2009

GEMCITABINE-OXALIPLATIN COMBINATION (SEGEMOX) IN ANTHRACYCLINE (A) AND TAXANES (T) PRETREATED METASTATIC BREAST CANCER (MBC): RESULTS FROM THE GERCOR-SEGEMOX PHASE II TRIAL
Author(s): Gligorov, J ; Cals, L ; Tournigand, C ; Merad, Z ; Dutel, J ; Selle F ; Zeghib, N ; Chibaudel, B ; Cvitkovic, F
Conference: 45th Annual Meeting of the American-Society-of-Clinical-Oncology
Location: Orlando, FL Date: MAY 29-JUN 02, 2009
Sponsor(s): Amer Soc Clin Oncol
Source: JOURNAL OF CLINICAL ONCOLOGY Volume: 27 Issue: 15 Supplement: S Meeting
Abstract: 1108 Published: MAY 20 2009

COMBINED TOPOTECAN AND LAPATINIB IN PATIENTS WITH EARLY RECURRENT OVARIAN OR PERITONEAL CANCER AFTER FIRST LINE OF PLATINUM-BASED CHEMOTHERAPY: A FRENCH FEDEGYN-FNCLCC PHASE II TRIAL
Author(s): Joly, F ; Weber, B ; Pautier, P ; Fabbro, M ; Selle F ; Krieger, S ; Leconte, A ; Bourgeois, H ; Henry-Amar, M
Conference: 45th Annual Meeting of the American-Society-of-Clinical-Oncology
Location: Orlando, FL Date: MAY 29-JUN 02, 2009
Sponsor(s): Amer Soc Clin Oncol
Source: JOURNAL OF CLINICAL ONCOLOGY Volume: 27 Issue: 15 Supplement: S Meeting
Abstract: 5555 Published: MAY 20 2009
Times Cited: 0 (from Web of Science)

A PHASE II TRIAL OF HIGH-DOSE CHEMOTHERAPY (HDCT) SUPPORTED BY HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS (PTS) WITH DISSEMINATED GERM-CELL TUMORS (GCTS) FAILING CHEMOTHERAPY AND WITH ADVERSE PROGNOSTIC FACTORS: THE TAXIF II PROTOCOL
Author(s): Lotz, J ; Selle F ; Fizazi, K ; Gravis, G ; Bul, B ; Delva, R ; Bay, J ; Baron, A ; Robain, M ; Biron, P
Conference: 45th Annual Meeting of the American-Society-of-Clinical-Oncology
Location: Orlando, FL Date: MAY 29-JUN 02, 2009
Sponsor(s): Amer Soc Clin Oncol
Source: JOURNAL OF CLINICAL ONCOLOGY Volume: 27 Issue: 15 Supplement: S Meeting
Abstract: 5028 Published: MAY 20 2009

JOINT DISORDERS FREQUENCY AND STRUCTURAL CHANGES DURING ANASTROZOLE ADJUVANT TREATMENT IN EARLY BREAST CANCER: A PROSPECTIVE TRIAL (DS392L00013)
Author(s): Delozier, T ; Daban, A ; Dieras, V ; Gligorov J et al.
Conference: 32nd Annual San Antonio Breast Cancer Symposium
Location: San Antonio, TX Date: DEC 09-13, 2009
Source: CANCER RESEARCH Volume: 69 Issue: 24 Supplement: 3 Pages: 527S-527S Published: DEC 15 2009
ADDITION OF BIBW 2992, AN IRREVERSIBLE INHIBITOR OF EGFR/HER1 AND HER2 INHIBITOR, TO TREATMENT CONTINUATION OF LETROZOLE IN ESTROGEN RECEPTOR (ER-) POSITIVE METASTATIC BREAST CANCER PROGRESSING ON LETROZOLE

Author(s): Gunzer, K.; Joly, F.; Delozier, T.; Gligorov J et al.
Conference: 32nd Annual San Antonio Breast Cancer Symposium
Location: San Antonio, TX Date: DEC 09-13, 2009
Source: CANCER RESEARCH Volume: 69 Issue: 24 Supplement: 3 Pages: 739S-739S Published: DEC 15 2009

A VERY FAVOURABLE MAMMOGRAPHIC SCREENING IMPACT ON BREAST CANCER CHARACTERISTICS AND TREATMENT MODALITIES IN FRANCE. ANALYSIS OF 2806 CASES.

Author(s): Cutuli, B.; Dalenc, F.; Guastalla, J-P; Gligorov J et al.
Conference: 32nd Annual San Antonio Breast Cancer Symposium
Location: San Antonio, TX Date: DEC 09-13, 2009
Source: CANCER RESEARCH Volume: 69 Issue: 24 Supplement: 3 Pages: 708S-708S Published: DEC 15 2009
Times Cited: 0 (from Web of Science)

RENAI Function EVOLUTION IN CANCER PATIENTS RESULTS OF THE IRMA-2 STUDY

Author(s): Oudard, S.; Janus, N.; Gligorov J; et al.
Conference: 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology
Location: Berlin, GERMANY Date: SEP 20-24, 2009
Sponsor(s): European Canc Org; European Soc Med Oncol
Source: EJC SUPPLEMENTS Volume: 7 Issue: 2 Pages: 177-178 Published: SEP 2009

PREVALENCE AND MANAGEMENT OF OROPHARYNGEAL CANDIDIASIS IN CANCER PATIENTS: RESULTS OF A PROSPECTIVE FRENCH MULTICENTRIC SURVEY

Author(s): Azria, D.; Gligorov J
Conference: 45th Annual Meeting of the American-Society-of-Clinical-Oncology
Location: Orlando, FL Date: MAY 29-JUN 02, 2009
Sponsor(s): Amer Soc Clin Oncol

PREVALENCE OF RENAL INSUFFICIENCY IN CANCER PATIENTS: DATA FROM THE IRMA-2 STUDY

Author(s): Janus, N.; Oudard, S.; Beuzeboc, P.; Gligorov J et al.
Conference: 45th Annual Meeting of the American-Society-of-Clinical-Oncology
Location: Orlando, FL Date: MAY 29-JUN 02, 2009
Sponsor(s): Amer Soc Clin Oncol

ADJUVANT ENDOCRINE TREATMENT OF BREAST CANCER

Author(s): Gligorov, J; Namer, M
Conference: Educational Cancer Convention (ECCLU)
Location: Lugano, SWITZERLAND Date: JUL 02-04, 2009
Sponsor(s): European Sch Oncol
Source: ANNALS OF ONCOLOGY Volume: 20 Pages: 7-7 Published: 2009
FRENCH EXPERIENCE OF PATIENTS' MANAGEMENT WHEN RECEIVING VINORELBINE ORAL CHEMOTHERAPY (NVBO) FOR A METASTATIC BREAST CANCER: FIRST RESULTS OF A PROSPECTIVE OBSERVATIONAL SURVEY ON PRACTICES
Author(s): Lotz JP; Husseini, F ; Finck, M ; Rotarski, M ; Bastit, L ; Riviere, A ; Youssef, A ; Mouysset, J ; Nahon, S ; Biville, F
Conference: 33rd European-Society-for-Medical-Oncology Congress
Location: Stockholm, SWEDEN Date: SEP 12-16, 2008
Sponsor(s): European Soc Med Oncol
Source: ANNALS OF ONCOLOGY Volume: 19 Pages: 73-73 Published: SEP 2008

RARE OVARIAN CANCERS (ROC) IN FRANCE: ANALYSIS OF THE FIRST 100 PATIENTS (PTS) PROSPECTIVELY INCLUDED THROUGH AN ON-LINE OBSERVATORY
Author(s): Ray-Coquard, I ; Guastalla, JP ; Lotz JP ; Weber, B ; Mayeur, D ; Orfeuvre, H ; Provençal, J ; Guardiola, E ; Paraiso, D ; Pujade-Lauraine, E
Conference: 33rd European-Society-for-Medical-Oncology Congress
Location: Stockholm, SWEDEN Date: SEP 12-16, 2008
Sponsor(s): European Soc Med Oncol
Source: ANNALS OF ONCOLOGY Volume: 19 Pages: 211-211 Published: SEP 2008

BREAST CONSERVATION IN THE TREATMENT OF T2 BREAST TUMORS ANALYSIS OF 1988-2003 SEER DATA
Author(s): Rouzier, R.; Lesieur, B.; Gligorov J; et al.
Conference: 31st Annual San Antonio Breast Cancer Symposium
Location: San Antonio, TX Date: DEC 10-14, 2008
Source: CANCER RESEARCH Volume: 69 Issue: 2 Pages: 345S-346S Published: JAN 15 2009

THE EFFICACY AND SAFETY OF NON-PEGYLATED LIPOSOMAL DOXORUBICIN MYOCET AND DOCETAXEL AS FRONT LINE TREATMENT IN HER2-NEU NEGATIVE METASTATIC BREAST CANCER PATIENTS: RESULTS OF A PHASE II TRIAL
Author(s): Cals, L.; Facchini, T.; Dohollou, N.; Gligorov J et al.
Conference: 33rd European-Society-for-Medical-Oncology Congress
Location: Stockholm, SWEDEN Date: SEP 12-16, 2008
Sponsor(s): European Soc Med Oncol
Source: ANNALS OF ONCOLOGY Volume: 19 Pages: 67-67 Published: SEP 2008

CLINICAL IMPACT OF UPFRONT ADJUVANT AROMATASE INHIBITOR (AI) THERAPY
Author(s): Gligorov J; Azria, D.; Namer, M.
Conference: 6th European Breast Cancer Conference
Location: Berlin, GERMANY Date: APR 15-19, 2008
Source: EJC SUPPLEMENTS Volume: 6 Issue: 7 Pages: 120-120 Published: APR 2008